RUNX2 is a bone-specific transcriptional regulator, aberrantly expressed in metastatic prostate cancer cells [40] and BIRC2, also known as Inhibitor of Apoptosis (IAP) plays key role in drug resistance and survival of cancer cells through inhibition of apoptosis [41]. Here, RUNX2 is linked to prostate carcinoma.